Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial
Authors' conclusion
In conclusion, semaglutide reduced MACE versus placebo in patients at risk for substantial liver fibrosis, as seen in the overall SELECT population.
Study context
- Population
- SELECT patients with atherosclerotic CVD and obesity but without diabetes, at high risk for substantial liver fibrosis
- Comparison
- Once-weekly subcutaneous semaglutide vs placebo
- Primary endpoint
- MACE (composite of cardiovascular death, nonfatal MI or nonfatal stroke) in subgroups by baseline Fibrosis-4 score
Methodological detailsprespecified secondary analysis
- Prespecified secondary analysis
Primary result
As reported in the abstract
MACE (CV death, nonfatal MI or nonfatal stroke) in subgroups at high risk of liver fibrosis
Baseline Fibrosis-4 ≥ 1.3: Major adverse cardiovascular events (MACE) reduced by 26%, HR
0.74 (0.63-0.88); P = 0.0004 (95% CI)
Age-specific Fibrosis-4 (≥1.3 (<65 years) or ≥2.0 (≥65 years)): MACE reduced by 21%, HR
0.79 (0.63-0.98); P = 0.035 (95% CI)
Any age with Fibrosis-4 > 2.67: MACE reduced by 34%, HR
0.66 (0.39-1.10); P = 0.11 (95% CI)
Further findings
| Outcome | HR (95% CI) | P value |
|---|---|---|
| Fatty liver index · 104 weeks28% greater decrease with semaglutide | 0.72 (0.71–0.73) | P < 0.0001 |
Original publication
Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial. Nat Med. Published 2 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →